• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

强迫症的心理药物治疗:综述

The psychopharmacological treatment of obsessive-compulsive disorder: a review.

作者信息

Insel T R, Murphy D L

出版信息

J Clin Psychopharmacol. 1981 Sep;1(5):304-11. doi: 10.1097/00004714-198109000-00006.

DOI:10.1097/00004714-198109000-00006
PMID:6174553
Abstract

This article reviews the literature concerning obsessive-compulsive disorder (OCD) and its treatment with drugs. We survey the differential diagnosis of OCD and the problems involved in evaluating its severity in a research setting. Pharmacological treatment of OCD has usually involved antidepressants, especially clomipramine, with equivocal but nevertheless encouraging success. Anxiolytic and neuroleptics have also been tried, but the results are inconsistent. We discuss the implications of these findings for treatment of patients with OCD and for future research.

摘要

本文综述了有关强迫症(OCD)及其药物治疗的文献。我们调查了强迫症的鉴别诊断以及在研究环境中评估其严重程度所涉及的问题。强迫症的药物治疗通常涉及抗抑郁药,尤其是氯米帕明,其效果虽不明确但仍令人鼓舞。也尝试过使用抗焦虑药和抗精神病药,但结果并不一致。我们讨论了这些发现对强迫症患者治疗及未来研究的意义。

相似文献

1
The psychopharmacological treatment of obsessive-compulsive disorder: a review.强迫症的心理药物治疗:综述
J Clin Psychopharmacol. 1981 Sep;1(5):304-11. doi: 10.1097/00004714-198109000-00006.
2
Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial.氯米帕明治疗强迫症。I. 一项对照临床试验。
Arch Gen Psychiatry. 1980 Nov;37(11):1281-5. doi: 10.1001/archpsyc.1980.01780240079009.
3
Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial.氯米帕明与去甲替林联合治疗强迫症:一项双盲、安慰剂对照试验。
J Clin Pharm Ther. 1998 Apr;23(2):155-9. doi: 10.1046/j.1365-2710.1998.00156.x.
4
Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder.强迫症患者停用氯米帕明后症状复发。
Am J Psychiatry. 1988 Dec;145(12):1521-5. doi: 10.1176/ajp.145.12.1521.
5
Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.多中心、双盲、氟伏沙明与氯米帕明治疗强迫症的比较
Int Clin Psychopharmacol. 2000 Mar;15(2):69-76. doi: 10.1097/00004850-200015020-00002.
6
Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison.
Arch Gen Psychiatry. 1989 Dec;46(12):1088-92. doi: 10.1001/archpsyc.1989.01810120030006.
7
Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.药物治疗强迫症的疗效:一项荟萃分析综述
Br J Psychiatry. 1995 Apr;166(4):424-43. doi: 10.1192/bjp.166.4.424.
8
Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder.氯米帕明、氯硝西泮和可乐定治疗强迫症
J Clin Psychopharmacol. 1992 Dec;12(6):420-30.
9
Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients.氯米帕明与强迫症:一项针对32名患者的安慰剂对照双盲研究。
J Clin Psychiatry. 1990 Jul;51(7):292-7.
10
Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy.氯米帕明与氟西汀治疗强迫症的疗效及副作用回顾性对比研究
J Clin Psychopharmacol. 1990 Apr;10(2):122-4. doi: 10.1097/00004714-199004000-00008.

引用本文的文献

1
Successful treatment of obsessive-compulsive disorder with zimelidine, a serotonin re-uptake inhibitor.齐美定(一种 5-羟色胺再摄取抑制剂)成功治疗强迫症。
Indian J Psychiatry. 1983 Jul;25(3):226-8.
2
Obsessive Compulsive Disorder: Improving prognosis through therapy and drug treatment.强迫症:通过治疗和药物治疗改善预后。
Can Fam Physician. 1991 Jun;37:1449-55.
3
D-amphetamine in obsessive-compulsive disorder.
Psychopharmacology (Berl). 1983;80(3):231-5. doi: 10.1007/BF00436159.
4
Effects of yohimbine in obsessive compulsive disorder.育亨宾在强迫症中的作用。
Psychopharmacology (Berl). 1987;93(3):308-13. doi: 10.1007/BF00187248.